DaVita (NYSE:DVA – Get Free Report) had its price objective lowered by UBS Group from $142.00 to $113.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective points to a potential upside of 17.51% from the company’s previous close.
DVA has been the subject of a number of other reports. Truist Financial reduced their price target on shares of DaVita from $115.00 to $104.00 and set a “hold” rating for the company in a research note on Wednesday, October 11th. StockNews.com began coverage on shares of DaVita in a report on Thursday, October 5th. They issued a “buy” rating on the stock. Finally, TheStreet downgraded shares of DaVita from a “b-” rating to a “c” rating in a report on Monday, October 23rd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has a consensus rating of “Moderate Buy” and an average target price of $102.67.
DaVita Stock Performance
DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $2.85 EPS for the quarter, topping analysts’ consensus estimates of $1.92 by $0.93. DaVita had a net margin of 5.11% and a return on equity of 63.38%. The firm had revenue of $3.12 billion during the quarter, compared to analyst estimates of $3.02 billion. During the same period in the previous year, the business posted $1.45 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. As a group, equities research analysts expect that DaVita will post 8.17 earnings per share for the current year.
Insider Buying and Selling at DaVita
In other DaVita news, insider Kathleen Alyce Waters sold 9,794 shares of DaVita stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $101.81, for a total transaction of $997,127.14. Following the transaction, the insider now owns 81,297 shares of the company’s stock, valued at $8,276,847.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.40% of the company’s stock.
Hedge Funds Weigh In On DaVita
Large investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its position in shares of DaVita by 48.4% during the first quarter. Commonwealth Equity Services LLC now owns 38,997 shares of the company’s stock valued at $3,163,000 after buying an additional 12,726 shares during the last quarter. KBC Group NV raised its position in shares of DaVita by 73.8% during the first quarter. KBC Group NV now owns 45,299 shares of the company’s stock valued at $3,674,000 after buying an additional 19,228 shares during the last quarter. Bessemer Group Inc. raised its position in shares of DaVita by 55.1% during the first quarter. Bessemer Group Inc. now owns 445 shares of the company’s stock valued at $36,000 after buying an additional 158 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of DaVita by 176.1% during the second quarter. Assenagon Asset Management S.A. now owns 13,086 shares of the company’s stock valued at $1,315,000 after buying an additional 8,347 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of DaVita by 146.1% during the second quarter. Victory Capital Management Inc. now owns 6,100 shares of the company’s stock valued at $613,000 after buying an additional 3,621 shares during the last quarter. Hedge funds and other institutional investors own 84.69% of the company’s stock.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Five stocks we like better than DaVita
- What Are Defense Contractor Stocks? How to Invest in Defense
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- MarketBeat Week in Review – 11/13 – 11/17
- 3 Monster Growth Stocks to Buy Now
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.